Therapeutic guide for mTOuRing through the braided kidney cancer genomic river
Abstract mTORC1 inhibitors were first approved for the use in metastatic kidney cancer.
However, observed treatment benefit was highly heterogeneous among patients. Through
case-based cancer genomic sequencing of therapeutic outliers, we can begin to appreciate
the convergent evolution of given cancer pathways/phenotypes beyond genes in kidney
cancer, like a braided river. Clin Cancer Res; 22 (10); 2320–2.© 2016 AACR. See related
article by Kwiatkowski et al., p. 2445
However, observed treatment benefit was highly heterogeneous among patients. Through
case-based cancer genomic sequencing of therapeutic outliers, we can begin to appreciate
the convergent evolution of given cancer pathways/phenotypes beyond genes in kidney
cancer, like a braided river. Clin Cancer Res; 22 (10); 2320–2.© 2016 AACR. See related
article by Kwiatkowski et al., p. 2445
Abstract
mTORC1 inhibitors were first approved for the use in metastatic kidney cancer. However, observed treatment benefit was highly heterogeneous among patients. Through case-based cancer genomic sequencing of therapeutic outliers, we can begin to appreciate the convergent evolution of given cancer pathways/phenotypes beyond genes in kidney cancer, like a braided river. Clin Cancer Res; 22(10); 2320–2. ©2016 AACR.
See related article by Kwiatkowski et al., p. 2445
AACR